Clover Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Key information
6.6%
Earnings growth rate
8.9%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 151.8% |
| Return on equity | n/a |
| Net Margin | -352.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth
Mar 17
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?
Nov 29Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?
Aug 31We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely
Apr 28Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate
Feb 05Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Clover Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 39 | -139 | 254 | 650 |
| 30 Sep 23 | 20 | -402 | 285 | 823 |
| 30 Jun 23 | 0 | -665 | 317 | 996 |
| 31 Mar 23 | 0 | -1,559 | 364 | 1,230 |
| 31 Dec 22 | 0 | -2,452 | 410 | 1,465 |
| 30 Sep 22 | 0 | -4,145 | 428 | 1,757 |
| 30 Jun 22 | 0 | -5,838 | 446 | 2,048 |
| 31 Mar 22 | 0 | -5,927 | 396 | 1,937 |
| 31 Dec 21 | 0 | -6,016 | 346 | 1,826 |
| 31 Dec 20 | 0 | -913 | 76 | 228 |
Quality Earnings: 2197 is currently unprofitable.
Growing Profit Margin: 2197 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2197 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare 2197's earnings growth over the past year to its 5-year average as it is currently unprofitable